drugset / Trial / NCT04355520
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a open-label, multicenter phase Ib study to evaluate safety and efficacy of TQ-B3525 tablets combined with fulvestrant injection in subjects with HR-positive, HER2-negative and PIK3CA mutation advanced breast cancer.
Timeline
- Start
- 2020-07
- Primary completion
- 2021-06
- Completion
- 2021-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQ-B3525 | Small molecule | 20 mg | Oral |
| Subject | TQ-B3525 | Small molecule | 30 mg | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | Intravenous |